CogState releases details of UBC agreement
Tuesday, 29 July, 2008
Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.
Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.
CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.
Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.
Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
